GlassScriptPhysician profile
Marcos A Benitez
NPI 1013022979
$7,169.43
in general payments reported to CMS, 2019-2025
42 companies · $692 in 2025
The $692 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,523 · 2020: $1,076 · 2021: $800 · 2022: $1,160 · 2023: $274 · 2024: $644 · 2025: $692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,610.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,609.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,221.60 | 2019-2025 | Ajovy, Austedo Xr |
| Abbvie INC. | $859.62 | 2021-2025 | Qulipta, Ubrelvy |
| Amgen INC. | $683.94 | 2019-2025 | Repatha, Aimovig |
| Supernus Pharmaceuticals, INC. | $558.03 | 2019-2021 | |
| Sk Life Science, INC. | $469.66 | 2020-2025 | |
| Ucb, INC. | $414.16 | 2019-2025 | Fintepla |
| Emd Serono, INC. | $383.56 | 2019-2022 | |
| Pfizer INC. | $281.00 | 2019-2025 | |
| Amneal Pharmaceuticals LLC | $274.75 | 2019-2025 | Rytary, Crexont |
| Novartis Pharmaceuticals Corporation | $238.38 | 2020-2025 | |
| Sunovion Pharmaceuticals INC. | $233.82 | 2019 | |
| Lilly USA, LLC | $218.06 | 2019-2022 | |
| Daiichi Sankyo INC. | $194.54 | 2019 | |
| Lundbeck LLC | $168.09 | 2022-2025 | Rexulti, Vyepti |
| Mdd US Operations, LLC | $92.30 | 2019-2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcos Benitez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.